Kassirer Asset Management Corp purchased a new position in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the medical instruments supplier’s stock, valued at approximately $6,322,000. C.R. Bard comprises 4.6% of Kassirer Asset Management Corp’s investment portfolio, making the stock its 2nd largest position.
Other institutional investors also recently made changes to their positions in the company. SRS Capital Advisors Inc. raised its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares during the period. Burns J W & Co. Inc. NY raised its position in shares of C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares during the period. Creative Planning raised its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the period. Blair William & Co. IL raised its position in shares of C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock worth $865,000 after buying an additional 30 shares during the period. Finally, First Merchants Corp raised its position in shares of C.R. Bard by 0.6% in the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock worth $1,623,000 after buying an additional 32 shares during the period. Institutional investors own 85.32% of the company’s stock.
C.R. Bard, Inc. (NYSE:BCR) traded up 0.19% during midday trading on Friday, reaching $319.75. 330,226 shares of the company traded hands. The stock has a market capitalization of $23.24 billion, a price-to-earnings ratio of 41.98 and a beta of 0.59. The firm has a 50 day moving average of $319.00 and a 200-day moving average of $283.44. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.54 EPS. Analysts forecast that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.
ILLEGAL ACTIVITY NOTICE: “Kassirer Asset Management Corp Acquires New Position in C.R. Bard, Inc. (BCR)” was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/13/kassirer-asset-management-corp-purchases-new-stake-in-c-r-bard-inc-bcr-updated.html.
A number of equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target on the stock in a report on Tuesday, June 13th. BMO Capital Markets lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 target price on the stock. in a report on Tuesday, April 25th. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. BidaskClub lowered shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and a consensus price target of $285.67.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.80% of the stock is owned by corporate insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.